Rein Therapeutics Insider Award: 17.5k Options to Director Aivado

Rhea-AI Filing Summary

Form 4 filing: Rein Therapeutics (RNTX) disclosed that director Manuel Aivado was granted a stock option for 17,500 common shares on 23-Jul-2025 at an exercise price of $1.55 per share, expiring 22-Jul-2035.

The option vests 100 % on the earlier of 23-Jul-2026 or the 2026 annual meeting, subject to continued board service. No open-market purchases or sales of common stock were reported, and Aivado’s post-transaction derivative holdings total 17,500 options, all held directly.

This is a routine equity-based compensation grant that does not immediately alter the public float or cash position. If exercised, the award would introduce only modest dilution, typical for small-cap governance practices, while further aligning the director’s interests with shareholders.

Positive

• Equity-based award encourages director focus on stock performance, strengthening governance alignment.

Negative

• Creates 17,500 potential new shares, adding slight dilution upon exercise.

Insights

Corporate Governance Analyst

TL;DR: Standard director option grant; neutral near-term impact, minor future dilution, aligns incentives.

The filing reflects customary board compensation. With a $1.55 strike, value accrues only if RNTX’s share price rises, encouraging performance alignment. The 17,500-share size is small versus typical micro-cap floats, so prospective dilution is negligible. No insider buying or selling signals were provided, keeping sentiment unchanged. Investors should view the event as administratively routine rather than a catalyst.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Aivado Manuel

(Last) (First) (Middle)

C/O REIN THERAPEUTICS, INC

12407 N. MOPAC EXPY. SUITE 250 #390

(Street)

AUSTIN TX 78758

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Rein Therapeutics, Inc. [ RNTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
07/23/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.55	07/23/2025		A		17,500		(1)	07/22/2035	Common Stock	17,500	$0.00	17,500	D

Explanation of Responses:

1. This option was granted on July 23, 2025. The shares underlying the option are scheduled to vest in full on the earlier of (i) July 23, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to continued service.

	/s/ Brian Windsor, attorney-in-fact for Manuel Aivado	07/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did RNTX report on 23-Jul-2025?

Director Manuel Aivado received an option grant for 17,500 shares at a $1.55 strike price.

When do Manuel Aivado’s RNTX options vest?

They vest fully on 23-Jul-2026 or the date of the 2026 annual meeting, whichever occurs first.

What is the expiration date of the granted options?

22-Jul-2035.

How many RNTX shares does the director own after the transaction?

Aivado holds 17,500 derivative securities (options); no common shares were disclosed.

Does the filing signal immediate dilution for RNTX shareholders?

No. Dilution occurs only if the options are exercised in the future.